The TFN Complete Guide to Biotech Penny Stocks
Today's Financial News - Posted July 24, 2009
In the course of our research to find the best biotech penny stocks, we compiled a list of all viable companies trading for less than $5 on U.S. exchanges. We appreciate that many of our TFN readers like to do their own analysis and hope this will prove a useful tool…
by The TFN Team
The following includes all the biotech stocks we could find trading on U.S. exchanges with a share price between 20 cents and $5.
***NOTE: ALL AMOUNTS LISTED ARE AS OF 09/16/2009.
Altus Pharmaceuticals, Inc. (NASDAQ:ALTU)
Share price: $0.23
Market Cap: $7.27 million
Altus Pharmaceuticals currently has three major projects in trial – one is a growth hormone that has completed Phase II adult trials and Phase I pediatric trials for the treatment of growth deficiencies, the other is an enzyme that has completed Phase I trials for the treatment of kidney stones. The company’s focus is the treatment of metabolic and digestive disorders.
http://www.altus.com
Neurogen Corp. (NASDAQ:NRGN)
Share price: $0.24
Market Cap: $16.69 million
Neurogen develops small-molecule drugs for the treatment of neurological and psychiatric disorders, specifically with the use of partial receptor agonists. Current projects include Phase II trials for the treatment of Parkinson’s and Restless Leg Syndrome (in separate trials), a completed Phase II trial for the treatment of insomnia, a completed Phase I trial for the treatment of anxiety and a current Phase II trial for the treatment of pain. Three independent drugs are being tested in these unique trials.
http://www.neurogen.com
Cortex Pharmaceuticals (AMEX:COR)
Share price: $0.24
Market Cap: $13.51 million
Cortex Pharmaceuticals was in the process of developing small molecule compounds for the treatment of neurological and psychiatric diseases, including Alzheimer’s and ADHD and by the end of 2008 had completed Phase II trials for the treatment of Alzheimer’s.
http://www.cortexpharm.com
Anesiva, Inc. (NASDAQ:ANSV)
Share price: $0.26
Market Cap: $10.52 million
Anesiva develops small molecule products for the treatment of post-surgical and musculo-skeletal pain. It’s lead product is undergoing Phase III trials for the treatment of post-operative knee replacement and bunionectomy care and Phase II trials for the treatment of post-operative hip replacement and arthroscopic surgical shoulder pain.
http://www.anesiva.com
Cell Genesys (NASDAQ:CEGE)
Share price: $0.33
Market Cap: $36.26 million
Cell Genesys is currently planning to merge with BioSante Pharmaceuticals. Operations include the development of gene therapies for neurodegenerative disorders.
http://www.cellgenesys.com
Market Cap: $7.12 million
Targeted Genetics has developed a proprietary protein delivery molecule, currently being used inconjunction with genetic therapy programs from third-parties to test the effectiveness in treatment of inflammatory arthritis, huntington’s disease, AIDs and congestive heart failure.
http://www.targen.com
Targeted Genetics Corporation (NASDAQ:TGEN)
Share price: $0.34
Palatin Technologies, Inc. (AMEX:PTN)
Share price: $0.38
Market Cap: $32.93 million
Palatin Technologies has several small molecule products in development, and is undergoing Phase II trials for two of them, one for heart failure and another for sexual dysfunction.
http://www.palatin.com
Market Cap: $7.85 million
VIA Pharmaceuticals works to develop compounds for the treatment of cardiovascual and metabolic diseases. Its lead compound treats vascular inflammation and has completed two Phase II trials for the treatment of cardiovascular diseases after a major event and is currently in-process of a Phase II trial for the treatment of patients with cellular inflammation related to insulin sensitivity/diabetes.
http://www.viapharmaceuticals.com
VIA Pharmaceuticals, Inc. (NASDAQ:VIAP)
Share price: $0.38
Metabasis Therapeutics, Inc. (NASDAQ:MBRX)
Share price: $0.41
Market Cap: $14.41 million
Metabasis Therapeutics has multiple metabolic and liver-related treatments in development; including a Phase II trial for the treatment of diabetes, a Phase I trial for the treatment of hypolipidemia, a Phase II trial for the treatment of Hepatitis B and a Phase I trial for Hepatitis C.
http://www.mbasis.com
Aastrom Biosciences, Inc. (NASDAQ:ASTM)
Share price: $0.41
Market Cap: $65.10 million
Aastrom Biosciences’ primary objective is to produce methods and commercialize the use of autologous cell products in the repair and regeneration of human tissue. The company is currently engaged in Phase II trials for the treatment of critical limb ischemia and dilated cardiomyopathy patients, using stem and early progenitor cells developed from the patient’s own bone marrow.
http://www.aastrom.com
EntreMed, Inc. (NASDAQ:ENMD)
Share price: $0.45
Market Cap: $39.54 million
EntreMed develops oncology treatment drugs, whose chief projects include a cell-cycle (growth) inhibitor and an aniogenic inhibitor. Phase II product trials of the lead product (panzem in IV and oral forms) have been completed for the treatment of prostate, ovarian and metastatic breast cancer; Phase II trials are underway for the treatment of renal cell carcinoma, non-small cell lung cancer, carcinoid and brain cancers and multiple myelomas.
http://www.entremed.com
deCODE Genetics, Inc. (NASDAQ:DCGN)
Share price: $0.51
Market Cap: $31.51 million
Decode Genetics currently has three cardio drugs in development, one which is undergoing Phase III trials for the treatment of heart attack, and two others that are undergoing Phase II trials for the treat ment of heart attack and arterial thrombosis, independently.
http://www.decode.com
Senesco Technologies, Inc. (AMEX:SNT)
Share price: $0.51
Market Cap: $31.51 million
Senesco Technologies’ product developments are based on the study of genes that regulate cell death in plants and humans. In human terms, they are specifically looking to target the genes of reproducing cancerous tumours, triggering their cell-death without targeting the dna of healthy cells.
http://www.senesco.com
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH)
Share price: $0.60
Market Cap: $17.62 million
Hollis-Eden Pharmaceuticals currently has two lead drug candidates that are undergoing clinical trial: the first is being used in three independent Phase II trials – one each for the treatment of type 2 diabetes, one for ulcerative colitis, and a third for the treatment of rheumatoid Arthritis; the second drug is undergoing a Phase II clinical trial for the treatment of prostate cancer.
http://www.holliseden.com
Hana Biosciences, Inc. (OTCBB:HNAB)
Share price: $0.60
Market Cap: $19.55 million
Hana Biosciences focuses on the treatment of cancer, with one drug that has completed Phase III trials for the treatment of acute lymphoblastic leukemia and melanoma, and another in Phase I testing for the treatment of breast and lung cancers.
http://www.hanabiosciences.com
Progen Pharmaceuticals, Ltd (NASDAQ:PGLA)
Share price: $0.62
Market Cap: $15.32 million
Progen Pharmaceuticals develops angiogenesis and cell proliferation therapies for the treatment of cancerous tumors. Current projects include: angiogenesis treatments – an ongoing Phase III trial for the treatment of post resection liver cancer, and an ongoing Phase II trial for the treatment of advanced melanomas.
http://www.progen.com.au
DARA BioSciences, Inc. (NASDAQ:DARA)
Share price: $0.64
Market Cap: $21.75 million
DARA BioSciences is a mid-stream development company, acquiring, developing and testing treatments for central nervous system and metabolic diseases. The current lead product is in Phase II testing for the treatment of neuropathic pain disorders. Preclinical projects include products for the treatment of type 2 diabetes and psoriasis.
http://www.darabiosciences.com
Cytomedix Inc. (AMED:GTF)
Share price: $0.65
Market Cap: $22.06 million
Cytomedix develops wound care and tissue regeneration technologies, and is the producer of an autologous wound care product called Autologel which creates platelet rich plasma from a patient’s own blood cells. The company is also developing a peptide intended for the treatment of inflammation.
http://www.cytomedix.com
RegenRx Biopharmaceuticals, Inc. (AMEX:RGN)
Share price: $0.67
Market Cap: $36.63 million
RegeneRx Biopharmaceuticals focuses on the development of peptide complexes for the protection and treatment of soft-tissue damage. The topical delivery candidate has completed Phase II trials for the treatment of pressure ulcers and is currently undergoing Phase II trials for the treatment of venous stasis ulcers and epidermolysis Bullosa. A second candidate is a peptide eye drop that is currently undergoing Phase II trials for the treatment of corneal wounds.
http://www.regenerx.com
Commonwealth Biotechnologies, Inc. (
Share price: $0.68
Market Cap: $5.56 million
Commonwealth Biotechnologies provides a wide range of support services to biotechnology research and trial operators, including the development and synthesis of proteins and antibodies; gene expression, analysis and synthesis; and immunogenic sequence studies.
http://www.cbi-biotech.com
Marshall Edwards, Inc. (NASDAQ:MSHL)
Share price: $0.69
Market Cap: $50.69 million
Marshall Edwards is a development stage company and wholly owned subsidiary of Novogen Ltd, developing cell-life cycle therapies for the treatment of cancer. Its current lead product is now in Phase III trials for the treatment of recurring ovarian and fallopian tumors and has been approved for a trial for use in the treatment of pancreatic cancer.
http://www.marshalledwardsinc.com
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM)
Share price: $0.74
Market Cap: $175.65 million
Peregrine Pharmaceuticals is currently researching and developing monoclonal antibodies for the treatment of cancer. Lead products include a drug that marks tumor cells for attack by the body’s existing white blood cells and an antibody that targets core cells of a tumor, delivering a radioactive isotope to the core of the mass. The first is currently in two Phase II trials for the treatment of breast and non-small cell lung cancer, respectively; the second is currently enrolling for a Phase II trial for the treatment of brain cancer.
http://www.peregrineinc.com
Generex Biotechnology Corp (NASDAQ:GNBT)
Share price: $0.78
Market Cap: $144.14 million
Generex Biotechnology focuses on the development of novel delivery systems for large molecule drugs. Their lead product, currently in Phase III clinical trials in the U.S., is an oral platform for the alternative delivery of insulin. Other potential applications include delivery of vaccines and steroids.
http://www.generex.com
Bionovo, Inc. (NASDAQ:BNVI)
Share price: $0.79
Market Cap: $60.53 million
Bionovo currently has two products in clinical trials: the first has completed Phase II trials for the treatment of hot flashes, the second has completed Phase I trials for the treatment of advanced breast cancer.
http://www.bionovo.com
GenVec, Inc. (NASDAQ:GNVC)
Share price: $0.80
Market Cap: $79.43 million
GenVec develops protein-effective gene therapies for the use in therapeutic drugs and vaccines. Its lead product is currently enrolling for a Phase III study on the treatment of pancreatic cancer (to be used in combination with radiation), and a safety, tolerability and proof of concept study for the use of the drug in combination with radiotherapies in the treatment of recurrent head and neck cancers.
http://www.genvec.com
Repros Therapeutics, Inc. (NASDAQ:RPRX)
Share Price: $0.84
Market Cap: $12.89 million
Repros Therapeutics is a developmental stage company whose current products include Proellex (designed to treat uterine fibroids and associated anemia) and Androxel (intended to treat male infertility). Proellex is currently undergoing clinical trials.
http://www.reprosrx.com
A.P. Pharma, Inc. (NASDAQ:APPA)
Share price: $0.85
Market Cap: $26.67 million
A.P. Pharma develops therapies using its polymer-based drug delivery technologies. It’s lead candidate has completed Phase III trials for the treatment of chemotherapy-induced nausea and vomiting; with a secondary drug in Phase II trials for the treatment of post-surgical pain.
http://www.appharma.com
Xoma Ltd (NASDAQ:XOMA)
Share price: $0.85
Market Cap: $140.88 million
Xoma has developed a group of antibody delivery technologies, which have proven successful in the development of Lucentis (for the treatment of age-related macular degeneration) and Cimzia (for the treatment of Rheumatoid Arthritis). The lead project in development is currently undergoing Phase II trials for the treatment of rheumatoid arthritis and Phase I trials for the treatment of inflammation associated with type 2 diabetes.
http://www.xoma.com
EpiCept Corporation (NASDAQ:EPCT)
Share price: $0.86
Market Cap: $113.61 million
EpiCept currently has one cancer drug pending approvial and another that is in Phase II trials for the treatment of brain cancer; as well as a third drug currently undergoing Phase III trials for the treatment of pain.
http://www.epicept.com
INSMED, Inc. (NASDAQ:INSM)
Share price: $0.86
Market Cap: $111.21 million
INSMED develops recombinant protein drugs, with a recently completed Phase II trial of a lead candidate in the development of Myotonic Muscular Dystrophy.
http://www.insmed.com
Adeona Pharmaceuticals, Inc. (AMEX:AEN)
Share price: $0.87
Market Cap: $18.67 million
Adeona Pharmaceuticals develops oral drug therapies for central nervous system and autoimmune diseases. Projects currently in trial include Phase III trials of independent products for the treatment of Age-related macular degeneration, Relapsing Remitting Multiple Sclerosis, and Rheumatoid Arthritis, and Phase II trials for unique products for the treatment of Fibromyalgia and Graft-vs-Host Disease.
http://www.adeonapharma.com
OrthoLogic Corporation/Capstone Therapeutics (NASDAQ:CAPS)
Share price: $0.89
Market Cap: $36.29 million
Capstone Therapeutics (formerly OrthoLogic Corp) has developed two promising synthetic amino acid compounds, one of which is currently being developed for the treatment of pulmonary disease.
http://www.capstonethx.comNeurobiological Technologies, Inc.. (NASDAY:NTII)
Share price: $0.89
Market Cap: $23.97 million
Neurobiological Technologies acquires and develops potential treatments for central nervous system and neurological disorders. Its drug product approved for the treatment of Alzheimer’s has just completed Phase III trials (run by a third party) for the treatment of swelling associated with brain tumors.
http://www.ntii.com
Discovery Laboratories, Inc. (NASDAQ:DSCO)
Share price: $0.91
Market Cap: $110.12 million
Discovery Labs has created a product that replicates the moist surfactant naturally produced by healthy lung tissue. Having completed Phase III trials for the treatment of pediatric respiratory conditions. FDA approval could be delayed in the short term given the new rules of comparing new drugs to existing approved products. In the long term they are working on developing the aerosolized form of the surfactant product for drug delivery.
http://www.discoverylabs.com
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)
Share Price: $0.98
Market Cap: $23.97 million
Cyclacel has two cancer drugs in one independent and one combined Phase II trials for the treatment of non-small cell lung cancer and myelodysplastic syndromes.
http://www.cyclacel.com
CytRX Corp. (NASDAQ:CYTR)
Share Price: $1.08
Market Cap: $118.25 million
CytRx develops treatments for cancer and neurodegenerative disorders using its small-molecule drug delivery technology. CytRx currently has two lead products in Phase II trials, one for the treatment of leukemia and one for ALS and stroke recovery treatments.
http://www.cytrx.com
LPath, Inc. (OTC:LPTN)
Share Price: $1.05
LPath Inc currently is currently developing two drug candidates, one in Phase 2 trials for the treatment of various cancers and one recently completed Phase 1 trials for the treatment of retinal degeneration.
http://www.lpath.com
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)
Share price: $1.09
Market Cap: $15.33 million
Catlyst is developing a drug line to treat addiction and obsessive-compulsive disorders. The current lead project includes a drug used outside the U.S. for the treatment of epilepsy that is currently undergoing a Phase II trial for the treatment of cocaine addiction.
http://www.catalystpharma.com
MiddleBrook Pharmaceuticals, Inc. (NASDAQ:MBRK)
Share Price: $1.10
Market Cap: $95.16 million
MiddleBrook Pharmaceuticals develops anti-infective drugs utilizing its proprietary rapid delivery technologies. The company’s product line includes both a fast-acting and a slow release antibiotic, and projects in development include a product for the treatment of respiratory infections and another for post-operative skin conditions.
http://www.middlebrookpharma.com
Icagen, Inc. (NASDAQ:ICGN)
Share price: $1.11
Market Cap: $52.33 million
Icagen has cloned the human ion channel genes and is using this data to develop ion channel drug therapies. Current clinical trials include a completed Phase I trial for the treatment of epilepsy and two Phase II trials for the treatment of asthma, one exercise induced, the other allergy induced.
http://www.icagen.com
Telik, Inc. (NASDAQ:TELK)
Share price: $1.14
Market Cap: $60.83 million
Telik develops and hopes to commercialize small molecule therapies for the treatment of cancer and other serious diseases. Its lead candidate has completed Phase III trials for the treatment of ovarian and non-small cell lung cancer; with secondary candidates enrolling in clinical trials for the treatment of Myelodysplastic syndrome and chemotherapy induced cytopenia.
http://www.telik.com
Athersys (NASDAQ:ATHX)
Share price: $1.19
Market Cap: $22.52 million
Athersys develops multi-stem cell treatments; currently in Phase I trials for the treatment of Acute Myocardial Infarction and Stroke; also researching for development of neurological-effective obesity treatments.
http://www.athersys.com
Inhibitex (NASDAX:INHX)
Share price: $1.19
Market Cap: $51.89 million
Inhibitex focuses on the development of anti-infective products; projects currently in trial include a Phase II trial of an antiviral for the treatment of shingles and a Phase II trial of a monoclonal antibody for the treatment of S. aureus infections.
http://www.inhibitex.com
Amarin Corp. PLC (NASDAQ:AMRN)
Share Price: $1.30
Market Cap: $35.20 million
Amarin is developing a variety of treatments for central nervous system disorders, including Huntington’s disease, hypertriblyceridemia and dyslipidemia. The lead product, a partially synthesized Omega-3 fatty acid, is currently in two independent Phase III trials for the treatment of hypertriglyceridemia and dyslipidemia.
http://www.amarincorp.com
MDRNA, Inc. (NASDAQ:MRNA)
Share Price: $1.34
Market Cap: $54.60 million
MDRNA develops and commercialize pharmaceuticals using RNA interference technology. The company’s current focus is on therapies for liver cancer.
http://www.mdrnainc.com
Pluristem Therapeutics, Inc. (NASDAQ:PSTI)
Share Price: $1.36
Market Cap: $17.33 million
Pluristem Therapeutics develops treatments for degenerative, ischemic and autoimmune disorders based on the use of allogenic cell therapy platforms. In the early stages of development, they appear to only have one Phase I trial in the works for the treatment of peripheral artery disease.
http://www.pluristem.com
Aeterna Zentaris, Inc. (NASDAQ:AEZS)
Share Price: $1.38
Market Cap: $80.74 million
AEterna Zentaris engages in the development of endocrine therapies and cancer treatments. In addition to an approved in vitro endocrine therapy, the company has two products in Phase II trials: one for the treatment of hormone-dependent prostate cancer, and one that targets the membrane signal functions of cancerous cells (targeted to non-small cell lung cancer, breast cancer, sarcoma and multiple myeloma).
http://www.zentaris.com
Curagen Corp. (NASDAQ:CRGN)
Share Price: $1.40
Market Cap: $80.09 million
CuraGen works to develop therapies for the treatment of cancer based on its antibody delivery platform. Curagen has one lead product for the treatment of cancer that is currently enrolling for two early-state Phase I/II trials for the treatment of Unresectable Stage III or IV Melanoma and locally advanced or metastatic breast cancer.
http://www.curagen.com
OXiGENE, Inc. (NASDAQ:OXGN)
Share Price: $1.40
Market Cap: $62.45 million
OXiGENE is a clinical-stage biopharmaceutical working to develop treatments for cancer and ophthalmic conditions based on a vascular disruption platform – essentially seeking out and neutralizing blood vessels that serve tumors. OXiGENE’s lead product is currently in a Phase III trial for the treatment of anaplastic thyroid cancer and two independent Phase II trials for the treatment of non-small cell lung cancer and platinum resistant ovarian cancer.
http://www.oxigene.com
Cell Therapeutics, Inc. (NASDAQ:CTIC)
Share Price: $1.42
Market Cap: $768.46 million
Cell Therapeutics develops and markets biopharmaceutical products for the treatment of cancer. Current portfolio includes Pixantrone, a Phase III tested drug used to treat aggressive, relapsed Non-Hodgkins Lymphoma, for which a New Drug Application has been submitted to the FDA. Also in development is Opaxio, a bonding drug carrier that is being developed to block chemotherapeutic drugs from attacking healthy cells.
http://www.cticseattle.com
Columbia Laboratories, Inc. (NASDAQ:CBRX)
Share Price: $1.47
Market Cap: $80.44 million
Columbia Laboratories develops and markets pharmaceutical products primarily for the treatment of women’s health conditions and endocrinologic disorders. Their chief biopharmaceutical product is a bioadhesive delivery system that permits the pharmaceutical to adhere to the site and delivered over time (in the case of women’s infertility treatments, the interior wall of the uterus) rather than being injected. Columbia laboratories has two further products in Phase I testing and another in Phase II testing.
http://www.columbialabs.com
Genetic Technologies, Ltd (NASDAQ:GENE)
Share Price: $1.47
Market Cap: $18.36 million
Genetic Technologies provides genetic research, testing and research and development projects, include testing associated with disease markers and genetic susceptibility.
http://www.gtg.com.au
Avigen, Inc. (NASDAQ:AVGN)
Share Price: $1.49
Market Cap: $44.45 million
Avigen is a development stage company whose lead product, a cell regulator, is being tested in Phase II trials for the treatment of neuropathic pain conditions.
http://www.avigen.com
Cel-Sci Corporation (AMEX:CVM)
Share price: $1.55
Market Cap: $231.80 million
Cel-Sci develops immunotherapy products, their lead project of which, Multikine, is currently planning a Phase III study for the treatment of oral cancer tumors and various tumors of the head and neck.
http://www.cel-sci.com
Corcept Therapeutics, Inc. (NASDAQ:CORT)
Share price: $1.57
Market Cap: $78.13 million
Corcept Therapeutics develops treatments for psychiatric and metabolic diseases. The company is currently enrolling two Phase III trials for the testing of its lead candidate, one for the treatment of Cushing’s Syndrome and the other for treatment of psychotic depression.
http://www.corcept.com
Adolor Corp. (NASDAQ:ADLR)
Share Price: $1.70
Market Cap: $78.77 million
Adolor engages in the discovery and development of biopharmaceutical pain relief therapies. The company currently has one medication approved by the FDA and marketed in conjunction with glaxosmithkline for the treatment of post-operative ileus; with two additional products in Phase II trials for the treatment of pain.
http://www.adolor.com
StemCells, Inc. (NASDAQ:STEM)
Share Price: $1.70
Market Cap: $183.98 million
StemCells focuses on the production, clinical development and commercialization of stem cell technologies. Focusing on the treatment of neurological disorders and diseases of the liver and pancreas, the two primary projects in Phase I trials are for the treatment of rare, but usually fatal neurological diseases that effect infants and young children.
http://www.stemcellsinc.com
Neuralstem, Inc. (AMEX:CUR)
Share price: $1.71
Market Cap: $59.08 million
Neuralstem is a developmental stage company that produces stem cells for regenerative therapies, and has a patent for a chemical compound that can stimulate new brain cell growth.
http://www.neuralstem.com
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)
Share Price: $1.75
Market Cap: $149.18 million
Angiotech Pharmaceuticals develops and markets technologies for acute and surgical applications. In addition to several approved products, projects in development include a gel sealant for pulmonary biopsy applications.
http://www.angiotech.com
Nile Therapeutics, Inc. (NASDAQ:NLTX)
Share Price: $1.75
Market Cap: $ 42.38 million
Nile Therapeutics is engaged in the development of treatments for cardiovascular disease, with two primary development lines of natriuretic peptides, with the goal of trials for the treatment of acute decompensated heart failure.
http://www.nilethera.com
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)
Share Price: $1.76
Market Cap: $26.79 million
Threshold Pharmaceuticals is focused on the discover and development of cancer treatments, specifically drugs targeting the solid tumors that are less-responsive to chemotherapy and radiation treatments. Currently has three product candidates in development, including one that attempts to treat hypoxic solild tumors, another to target glycolic processes of solid tumors and another to treat soft-tissue sarcomas, pancreatic and ovarian cancers and small cell lung cancer.
http://www.thresholdpharm.com
GTC Biotherapeutics, Inc.(NASDAQ:GTCB)
Share Price: $1.79
Market Cap: $18.78 million
GTC Biotherapuetics, Inc.is engaged in the development and production of therapeutic human recombinant proteins and monoclonal antibodies for the treatment of blood deficiencies, hemophilia and other coagulation disorders.
http://www.gtc-bio.com
Javelin Pharmaceuticals, Inc. (AMEX:JAV)
Share Price: $1.82
Market Cap: $110.42 million
Javelin Pharmaceuticals works to developed new and approved technologies for the delivery of pain therapies, including acute and chronic syndromes associated with post-operative and post-traumatic conditions. Lead product portfolio includes three unique pain relief therapies currently in Phase III testing, including and IV-deliverable NSAID which has been found to be well-tolerated by most patients for the treatment of post-operative pain and inflammation, including those with impaired renal function; an intranasal morphine delivery product for the treatment of acute pain and an intranasal ketamine delivery product for the treatment of acute moderate to severe pain.
http://www.javelinpharmaceuticals.com
Response Genetics, Inc. (NASDAQ:RGDX)
Share Price: $1.83
Market Cap: $28.00 million
Response Genetics is a clinical trial research provider, specifically engaged in conducting trials related to cancer therapies and chemotherapy combined trials.
http://www.responsegenetics.com
Prana Biotechnology, Ltd (NASDAQ:PRAN)
Share Price: $1.86
Market Cap: $36.79 million
Prana Biotechnology is a development stage company that studies the functions of proteins in the human brain, including how they are deposited, how and when they become toxic, and how synthetic proteins may be used as drug delivery shuttles in therapeutic treatments. Their lead commercial candidate is currently in Phase II trials for the treatment of Huntington’s Disease.
http://www.pranabio.com
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
Share Price: $1.86
Market Cap: $40.53 million
ZIOPHARM works to develop and commercialize small-molecule cancer therapies: currently conducting Phase II trials of a product to treat metastatic soft tissue sarcoma and PhaseI/II trials of anti-mitochondrial treatments for acute promyelocytic leukemia and other cancers.
http://www.ziopharm.com
AVI BioPharma (NASDAQ:AVII)
Share Price: $1.88
Market Cap: $161.17 million
AVI BioPharma develops RNA-platform drug therapies that operate by disrupting cell function of cancerous and diseased conditions. Its lead candidate is planning Phase II trial for the prevention of restenosis, with another candidate in Phase I trials for the treatment of Duchenne Muscular Dystrophy.
http://www.avibio.com
NovaBay Pharmaceuticals, Inc. (AMEX:NBY)
Share Price: $1.89
Market Cap: $41.53 million
NovaBay Pharmaceuticals develops synthetic anti-infective candidates with the goal of treating a range of infections without developing resistance.
http://www.novabaypharma.com
BioSante Pharmaceuticals (NASDAQ:BPAX)
Share Price: $1.92
Market Cap: $52.70 million
BioSante is a specialty pharmaceuticals company which is currently planning to merge/acquire Cell Genesys. The company’s current high-profile project in development is a Phase III study of a topical steroid intended to treat sexual dysfunction in menopausal women.
The merged company looks forward to expanding cellular cancer immunotherapy and vaccination enhancement projects in the long term.
http://www.biosantepharma.com
Pharmacyclics, Inc. (NASDAQ:PCYC)
Share Price: $1.94
Market Cap: $53.43 million
Pharmacyclics focuses on the development and production of small molecule synthetics. The company is currently testing four products in clinical trial for oncology treatments, including a product for the treatment of brain cancer, and products for the treatment of autoimmune disorders, allergies and asthma.
http://www.pharmacyclics.com
Acadia Pharmaceuticals, Inc. (NASDAQ:ACAD)
Share Price: $1.95
Market Cap: $72.77 million
Acadia Pharmaceuticals develops and markets products for the treatment of central nervous system disorders. Its lead candidate is currently in Phase III testing for the treatment of Parkinson’s disease psychosis, with an additional candidate in the Phase II testing for the treatment of chronic pain.
http://www.acadia-pharm.com
Cerus Corp. (NASDAQ:CERS)
Share Price: $2.06
Market Cap: $67.15 million
Cerus is a biomedical support company that develops and markets the INTERCEPT blood system, which has been approved for use in Europe, and is under Phase III trials for use in the United States; the INTERCEPT system disables pathogens in blood and bloodplasma.
http://www.cerus.com
Hemispherx Biopharma, Inc. (AMEX:HEB)
Share Price: $2.10
Market Cap: $265.10 million
Hemispherx Biopharma develops and manufactures drug therapies for the treatment of viral and immune-based disorders. The company’s lead products include an FDA-approved product for the treatment of a category of STD infection; and its lead development candidates include an RNA-based immunotherapy drug and an antiviral.
http://www.hemispherx.net
Antigenics, Inc. (NASDAQ:AGEN)
Share Price: $2.14
Market Cap: $190.79 million
Antigenics conducts develops biotech pharmaceuticals aimed at treating cancer and immunological diseases. Current products include Oncophage, a cancer vaccine that has completed Phase III trials for the treatment of kidney cancer and Phase II trials for the treatment of a specific brain cancer. Developmental projects include adjuvants specifically tested with vaccines in the treatment of immunological disorders including, but not limited to, herpes, influenza and malaria.
http://www.antigenics.com
Dynavax Technologies Corporation (NASDAQ:DVAX)
Share Price: $2.16
Market Cap: $86.23 million
Dynavax Technologies currently has three products ready for Phase I trials and three more currently under clinical trial operations. The lead product of these is HEPLISAV, a hepatitis B vaccine treatment that has completed Phase III testing for successfully providing increased protection (in fewer doses than the current vaccine) for patients of late-term renal disease. Pending projects include influenza vaccines and toll-receptor drugs for the treatment of asthma and other auto-inflammatory conditions.
http://www.dynavax.com
SeraCare Life Sciences, Inc. (NASDAQ:SRLS)
Share Price: $2.21
Market Cap: $41.22 million
SeraCare Life Sciences produces discovery and development technologies, support materials and research services; including plasma-derived reagents, diagnostic tools and contract research services.
http://www.seracare.com
AspenBio Pharma, Inc. (NASDAQ:APPY)
Share Price: $2.21
Market Cap: $71.18 million
AspenBio Pharma is focused on the commercialization of blood-based human diagnostic testing, including the diagnosis of appendicitis.
http://www.aspenbioinc.com
Oncolytics Biotech, Inc. (NASDAQ:ONCY)
Share Price: $2.23
Market Cap: $110.15 million
Oncolytics Biotech is developing a viral activated therapy that targets cancers cells by both attacking individual cancer cells and marking other cells for attach by the body’s own immune functions. The company currently has several ongoing Phase I/II and Phase II trials to further localize potential cancer conditions that could be effectively treated with this method.
http://www.oncolyticsbiotech.com
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX)
Share price: $2.26
Market Cap: $108.11 million
Keryx Biopharmaceuticals works to develop novel therapies for the treatment of serious diseases including diabetes and cancer. Its lead cancer therapy acts by targeting the cell’s death triggers and has completed Phase II trials. Its secondary project is developing a Phase II trial plan for treating hyperphosphatemia in patients with en-stage renal disease.
http://www.keryx.com
Curis, Inc. (NASDAQ:CRIS)
Share Price: $2.31
Market Cap: $153.48 million
Curis develops drugs based on the use of cellular signaling pathways, with its product focus being the treatment of cancer. Its lead drug candidate is currently undergoing three separate Phase II trials for the treatment of colorectal and ovarian cancers and advanced basal cell carcinomas.
http://www.curis.com
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND)
Share Price: $2.37
Market Cap: $267.82 million
Ligand Pharmaceuticals’ current development projects include: Phase III trials of drugs to treat menopausal symptoms and Hepatitis C and chronic liver disease and Phase II trials of drugs to treat COPD and asthma, psoriasis and atherosclerosis.
http://www.ligand.com
CombinatoRx, Inc. (NASDAQ:CRXX)
Share price: $2.38
Market Cap: $83.80 million
CombinatoRx develops drug candidates that work across multiple biological pathways – its current development line includes five candidates that have completed or are undergoing Phase II trials. The candidates include topical and capsule formulations of combination drugs, and trials have been developed for the treatment of immunoinflammator conditions including asthma, psoriasis, and diabetes.
http://www.combinatorx.com
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)
Share Price: $2.41
Market Cap: $80.14 million
Alexza Pharmaceuticals is focused on the development and commercialization of drug delivery products utilizing its condensed aerosol delivery system.
http://www.alexza.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Share Price: $2.41
Market Cap: $330.97 million
Lexicon Pharmaceuticals has developed an extensive genome library, that is the basis for a variety of human drug trials. Lexicon currently has four active trials up to Phase II, including separate trials for the treatment of carcinoid syndrome, irritable bowel syndrome and rheumatoid arthritis.
http://www.lexpharma.com
Monogram Biosciences, Inc. (NASDAQ:MGRM)
Share Price: $2.41
Market Cap: Not Available
Monogram Biosciences is engaged in the development of diagnostic tools to identify and localize treatment of infectious diseases and cancers. Monogram Biosciences is currently under acquisition by LabCorp.
http://www.monogrambio.com
Penwest Pharmaceuticals Co. (NASDAQ:PPCO)
Share Price: $2.45
Market Cap: $77.81 million
Penwest Pharmaceuticals is engaged the the discovery and development of therapies for the treatment of central nervous system disorders. Of its two lead products, one is in Phase II trials for the treatment of pain, the other is in Phase I trials for the treatment of mitochondrial respiratory chain diseases.
http://www.penwest.com
Opko Health Inc. (AMEX:OPK)
Share Price: $2.48
Market Cap: $626.62 million
Opko Health develops and markets treatments for ophthalmic conditions, include pharmaceuticals and drug delivery technologies, with a focus on acquiring complementary technologies.
http://www.opko.com
Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS)
Share Price: $2.50
Market Cap: $93.27 million
Anadys Pharmaceuticals is engaged in the development of treatments for cancer and Hepatitis C. Its current projects are all in Phase I trials and function by inhibiting cell function in cancer or viral conditions.
http://www.anadyspharma.com
Trimeris, Inc. (NASDAQ:TRMS)
Share Price: $2.54
Market Cap: $56.77 million
Trimeris engages in the research, development and commercialization of viral therapies. Its lead project, a viral fusion inhibitor targeting HIV, is currently in Phase I trials.
http://www.trimeris.com
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)
Share Price: $2.58
Market Cap: $280.72 million
ARIAD Pharmaceuticals conducts research and development into cancer therapies utilizing cell signaling therapies. Their lead candidate, which works by blocking proteins responsible for cellular growth is currently in a Phase III trial for the treatment of sarcomas and Phase II trials for breast, endometrial and prostate cancers.
http://www.ariad.com
Rosetta Genomics, Ltd. (NASDAQ:ROSG)
Share Price: $2.69
Market Cap: $38.13 million
Rosetta Genomics develops and commercializes microRNA based diagnostic and therapeutic products for the identification and treatment of various cancers.
http://www.rosettagenomics.comDURECT Corp (NASDAQ:DRRX)
Share Price: $2.69
Market Cap: $221.53 million
DURECT is a specialty pharmaceutical company whose delivery platforms include biodegradable implants, biodegradable microspheres, transdermal patches, and extended release oral capsules. The company has three products in Phase II trials, one is an inject able solution for the treatment for post-operative pain, the other two are independently tested for the treatment of chronic pain and post-herpetic neuralgia, each formulation using the transdermal patch delivery system.
http://www.durect.com
Array BioPharma Inc. (NASDAQ:ARRY)
Share Price: $2.81
Market Cap: $135.23 million
Array BioPharma develops and markets small molecule drugs designed to treat cancer, pain and inflammatory diseases. The company currently has three independent drugs in Phase II trials, one for cancer and two for inflammation and metabolic disorders.
http://www.arraybiopharma.com
EXACT Sciences Corp. (NASDAQ:EXAS)
Share Price: $2.82
Market Cap: $99.97 million
EXACT Sciences develops DNA-based technologies for non-invasive cancer detection. Currently produces and develops a detection product for identifying colorectal cancers.
http://www.exactsciences.com
RXi Pharmaceuticals Corp. (NASDAQ:RXII)
Share Price: $2.86
Market Cap: $46.35 million
RXi Pharmaceuticals is engaged in the discovery and development of therapies based on RNAi delivery technologies.
http://www.rxipharma.com
Compugen, Ltd. (NASDAQ:CGEN)
Share Price: $2.98
Market Cap: $85.05 million
Compugen conducts discovery, development and early-stage licensing of drug therapies and diagnostic biomarkers. Its predictive model platforms focus on cancer, cardiovascular and immune-related diseases; its practical activities include the discovery and isolation of diseases associated with peptide blockers, genomic markers, and targets for monoclonal antibodies.
http://www.cgen.com
SuperGen, Inc. (NASDAQ:SUPG)
Share Price: $3.00
Market Cap: $177.45 million
SuperGen is engaged in the discovery, acquisition, and development of cancer therapies. Their lead candidate is currently in PhaseI trials to evaluate its effectiveness as a mutant inhibitor.
http://www.supergen.com
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)
Share Price: $3.00
Market Cap: $177.24 million
Idenix Pharmaceuticals develops drugs to treat human viral diseases. In addition to a marketable product for the treatment of Hepatitis B, the company also has two independent drug candidates in Phase II trials, one for the treatment of HIV, the other for Hepatitis C.
http://www.idenix.com
Santarus, Inc. (NASDAQ:SNTS)
Share Price: $3.04
Market Cap: $177.04 million
Santarus is engaged in the acquisition, development and commercialization of products for the treatment of gastroenteritis and related conditions. It currently markets a product developed for the treatment of gastroenteritis that combines an antacid with a proton pump inhibitor.
http://www.santarus.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Share Price: $3.28
Market Cap: $128.21 million
Neurocrine Biosciences develops and markets therapies for the treatment of neurological and endocrine disorders. The company currently has three products in Phase II clinical trials, one for the treatment of endometriosis, one for anxiety and depression and the third for the treatment of cardiovascular disease.
http://www.neurocrine.com
Nabi Biopharmaceuticals (NASDAQ:NABI)
Share Price: $3.36
Market Cap: $170.56 million
Nabi Biopharmaceuticals develops products for the treatment of nicotine addiction and infectious diseases. Of its lead candidates, one is Phase III trials for the treatment of two strains of staph, and another is in Phase II trials for the treatment of nicotine addiction.
http://www.nabi.com
ARYx Therapeutics, Inc. (NASDAQ:ARYX)
Share Price: $3.40
Market Cap: $93.33 million
ARYx Therapeutics is engaged in the development of products using its RetroMetabolic Drug Design technology, which produces molecules that retain the strength of the drgu while buffering common adverse side effects. ARYx Therapeutics currently has three independent products in Phase II testing: one for gastrointestinal disorders, one for the treatment of atrial fibrillation, and an anticoagulant.
http://www.aryx.com
Cytokinetics, Inc. (NASDAQ:CYTK)
Share Price: $3.51
Market Cap: $213.38 million
Cytokinetics is develops therapies that regulate muscle function. Its lead product, a smooth muscle modulator intended to treat patients with a high risk of heart failure, is currently planning Phase II trials. The company is also conducting Phase II trials for the stabilization of heart failure using both IV and oral delivery trials.
http://www.cytokinetics.com
ARCA Biopharma, Inc. (NASDAQ:ABIO)
Share Price: $3.65
Market Cap: $27.71 million
ARCA Biopharma is engaged in the development of gene therapies for the treatment of cardiovascular diseases. Its leading candidate has completed Phase III trials and filed an application with the FDA for the treatment of chronic heart failure.
http://www.arcabiopharma.com
Gentium S.p.A (NASDAQ:GENT)
Share Price: $3.65
Market Cap: $54.59 million
Getium S.p.A is engaged in the development of a DNA-based drug platform, intended to treat and prevent hepatic veno-occlusive disease, which is often a result of conventional chemotherapy or radiation treatments for liver cancer.
http://www.gentium.it
Cytori Therapeutics, Inc. (NASDAQ:CYTX)
Share Price: $3.66
Market Cap: $134.72 million
Cytori Therapeutics develops and commercializes biotechnological regenerative products, including the autologous reneration of a patients own cells during surgical procedures, the banking and development of stem and regenerative cells and the development of stem and regenerative cell products. Available internationally, the primary product – a system to produce autologous cells during real-time surgical procedures – is currently under FDA review.
http://www.cytoritx.com
Depomed, Inc. (NASDAQ:DEPO)
Share Price: $3.82
Market Cap: $197.15 million
Depomed develops and markets products based on its oral delivery platforms. In addition to its commercial products (a type 2 diabetes treatment and a treatment for uncomplicated urinary tract infections) the company has two products in Phase III trials, one for hot flashes and one for the treatment of post herpetic heuralgia.
http://www.depomedinc.com
PharmAthene, Inc. (AMEX:PIP)
Share Price: $3.88
Market Cap: $110.30 million
PharmAthene focuses on the development and commercialization of biological and chemical defense products. Its leading projects include a recombinant protective antigene and a human monoclonal antibody for the treatment of anthrax poisoning, one of which is currently under FDA review
http://www.pharmathene.com
Opexa Therapeutics Inc. (NASDAQ:OPXA)
Share price: $4.06
Market Cap: $49.71 million
Opexa Therapeutics works to develop autologous cellular therapies for neurological conditions; their lead project recently concluded Phase II trials for the treatment of early relapsing multiple sclerosis.
http://www.opexatherapeutics.com
Cleveland BioLabs, Inc. (NASDAQ:CBLI)
Share Price: $4.08
Market Cap: $66.14 million
Cleveland BioLabs is engaged in the development of oncology therapies. Its lead candidate recently completed a Phase II trial for the treatment of prostate cancer.
http://www.cbiolabs.com
pSivida Corp (NASDAQ:PSDV)
Share Price: $4.20
Market Cap: $76.79 million
pSivida focuses on the development of ophthalmic and cancer therapies utilizing its miniaturized, slow release delivery platform. PSivida currently has two products approved by the FDA for the treatment of uveitis and AIDS-related cytomegalovirus retinits. Its lead research candidate is currently in Phase III trials for the treatment of diabetic macular edema.
http://www.psivida.com
Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
Share Price: $4.31
Market Cap: $132.66 million
Nymox Pharmaceutical is engaged in the development of drug therapies for cancers, bacterial infections and neurological diseases. Its products include a protein-based test to aid in the diagnosis of Alzheimer’s disease.
http://www.nymox.com
QLT, Inc. (NASDAQ:QLTI)
Share Price: $4.42
Market Cap: $237.82 million
QLT develops and markets drug therapies primarily for the treatment of ophthalmic diseases. In addition to an approved and marketed product for the treatment of subfield choroidal neovascularization, the company has two products in development, one for the treatment for age-related macular degeneration and one for the treatment of advanced prostate cancer.
http://www.qltinc.com
Cardiome Pharma Corp. (NASDAQ:CRME)
Share Price: $4.50
Market Cap: $287.37 million
Cardiome Pharma is engaged in the discovery and development of drugs to treat cardiovascular diseases. Its lead product is currently in Phase II trials for an oral delivery for the treatment of atrial fibrillation, the IV form of the same drug has been submitted to the FDA.
http://www.cardiome.com
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)
Share Price: $4.52
Market Cap: $214.96 million
NPS Pharmaceuticals is engaged in the development of drug therapies for the treatment of gastrointestinal and endocrine disorders. The company is currently two Phase III trials, one for the treatment of Parenteral nutrition dependency in patients with short bowel syndrome, the other for the treatment of hypoparathyroidism.
http://www.npsp.com
Vical, Inc. (NASDAQ:VICL)
Share Price: $4.59
Market Cap: $237.80 million
Vical is engaged in the discovery and development of drug therapies based on its DNA delivery technologies. Its lead products include a Phase III trial for the treatment of metastatic melanoma, a Phase II trial for treatment of hematopoietic cell transpant patients and a Phase I trial of an H5N1 vaccine delivered with a proprietary adjuvant.
http://www.vical.com
Evotec AG (NASDAQ:EVTC)
Share price: $4.62
Market Cap: $251.42 million
Evotec AG develops drug therapies for the treatment of neurological disorders, pain and inflammation. Its lead products are completing independent Phase I trials for the treatment of depression that has not responded to conventional treatments and rheumatoid arthritis. The company has several other products in development including treatments cognitive disorders, pain and inflammation.
http://www.evotec.com
Celsion Corporation (NASDAQ:CLSN)
Share Price: $4.66
Market Cap: $47.05 million
Celsion develops drugs for the treatment of cancer. Its lead product is currently in a Phase III trial for the treatment of liver cancer and a Phase II trial for the treatment of recurrent chest wall breast cancer.
http://www.celsion.com
Trinity Biotech, plc (NASDAQ:TRIB)
Share Price: $4.73
Market Cap: $98.65 million
Trinity Biotech is engaged in the acquisition, development and marketing of diagnostic products for use in the determination of autoimmune disorders, diabetes, and blood, liver and intestine disorders.
http://www.trinitybiotech.com
SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
Share Price: $4.77
Market Cap: $220.79 million
SciClone Pharmaceuticals currently marketed product is approved in multiple countries for the treatment of Hepatitis B, Hepatitis C, certain cancers and as a vaccine adjuvant. Current projects include Phase II trials for the treatment of pancreatic cancer and a separate trial for the treatment of oral mucositis.
http://www.sciclone.com
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Share Price: $4.78
Market Cap: $442.74 million
Arena Pharmaceuticals is currently completing Phase III trials of an obesity drug; as well as a variety of Phase I/II trials to include an independent product to treat arterial thrombosis, a product developed in conjunction with Merck pharmaceuticals to treat atherosclerosis and a product developed in conjunction with Ortho-McNeill-Janssen to treat Type 2 diabetes.
http://www.arenapharm.com
***You may also wish to read:
The TFN Complete Guide to Natural Gas Stocks
The TFN Complete Guide to Automotive Parts Manufacturers and Distributors
The TFN Complete Guide to Wind Energy Stocks
The TFN Complete Guide to Lithium Stocks
Next Article: Solar SunPower Corporation (SPWRA) is surging as predicted
Posted by Laura Cadden · Filed Under Featuring..., Investment Research, Investment Strategies, Politics, US Stocks and Markets
| 
5 Responses to “The TFN Complete Guide to Biotech Penny Stocks”
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down
August 30th, 2009 at 9:16 am
Hi:
I’d like to have some advice as to how to establish a decent portfolio and have the ability to track and place or withdraw certain investment transactions as per your recommendations.
I do not have any investing experience but am a fast learner – especially if I make a profit.
Regards,
Juergen Buche, ND
August 31st, 2009 at 12:40 pm
The most simple way is to open an account with the online broker of your choice, transfer a comfortable amount of “play money” from your bank account to your brokerage account… and simply pick the stock whose line of argument you agree with.
If by “decent” you mean a diversified portfolio, I’d be inclined to say “don’t bother about diversification.”
This is still an incredibly volatile market. And as the last two crashes (November 2008 and February 2009) have shown, there’s no asset that is really safe.
We think this is a great time to use select stocks to get a head-start in speculative investing. (Let’s face it: ALL investing at this point is speculative!)
Start small, with money you can truly afford to put at risk. And use any gains you make as capital for subsequent speculations!
October 18th, 2009 at 12:40 pm
Novadel (NVD) should be looked at based on their Oct. 16th press release whereby CEO states they are working on license deal by Y/E 2009. interesting play
October 19th, 2009 at 8:27 pm
The first thing you have to consider is the money you’ll allocate for buying each stock. As a rule, you must invest a very small amount of money in each stock that you research no matter how appealing the stock might look to you and no matter how much positive coverage it is recieving.
second set a price target at which you should be selling your shares. For example, you could set a 30 to 50% profit target and sell your shares no matter what. Take into consideration how much commissions you are paying and the amount you have invested. sometimes a small investment would have to go more than 100% in order for the investor to breakeven.
finally, educate your self on the industry.
check out the following site http://www.pennystocksmpire.com for more info.
November 4th, 2009 at 8:15 pm
Wednesday November 4, 2009
XOMA Ltd Granted First European Patent Covering XOMA 052